[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"luspatercept\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:luspatercept":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643343",false,"NCT07636486","Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Inclusion Criteria:\n\n* 18-65 years\n* Hematologic malignancies\n* Poor erythroid engraftment after the first allo-HSCT\n* Complete remission post-transplantation\n* Eastern Cooperative Oncology Group performance status of 0-2\n* Epoetin-naive\n* Endogenous serum erythropoietin concentration \\\u003C500 U\u002FL\n\nExclusion Criteria:\n\n* Life expectancy shorter than 30 days post-transplantation\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)","ALL","18 Years","65 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.",[27,28,29,30],"Luspatercept","Epoetin","Poor Erythroid Engraftment","Hematological Malignancies","NOT_YET_RECRUITING","2026-06-04",{"date":34,"type":35},"2026-06-09","ACTUAL",{"date":37,"type":20},"2026-06-15",{"date":39,"type":20},"2030-12-31",{"name":41,"class":42},"Nanfang Hospital, Southern Medical University","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":43},"100634445","NCT07539779","Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis","The Efficacy and Safety of Luspatercept in Preventing Poor Erythroid Engraftment After Allo-HSCT for Hematological Malignancies With Moderate to Severe Myelofibrosis: A Prospective, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18-65 years old, gender not restricted;\n* ECOG score 0-2 points;\n* Hematological malignancies with moderate to severe myelofibrosis\n* Willing to undergo the first allo-HSCT with a suitable donor\n* In a CR state before transplantation.\n\nExclusion Criteria:\n\n* Has previously undergone allo-HSCT;\n* ECOG score is 3-5;\n* Expected lifespan after transplantation is less than 30 days;\n* Has severe cardiac dysfunction, severe arrhythmia or severe pulmonary dysfunction (obstructive and\u002For restrictive ventilation disorder);\n* Has severe liver dysfunction, with liver function indicators (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL)) more than twice the upper limit of normal;\n* Has severe renal dysfunction, with creatinine (Cr) more than twice the upper limit of normal or 24-hour creatinine clearance rate (Ccr) lower than 30 ml\u002Fmin;\n* Has severe active bleeding;\n* Patients judged by the investigator to be unsuitable for participating in this trial.",{"count":51,"type":20},196,[23,24],"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with moderate to severe myelofibrosis (MF). Currently, there is a lack of effective prevention strategies for poor erythroid engraftment after transplantation. Luspatercept, a novel TGF-β superfamily signaling pathway modulator, has shown potential in small-sample studies for the treatment and prevention of post-transplant anemia. Given the high proportion and poor prognosis of poor engraftment function in hematological malignancies with moderate to severe myelofibrosis after transplantation, we plan to conduct a prospective, multicenter, randomized controlled study to explore the efficacy and safety of luspatercept in preventing poor erythroid engraftment after allo-HSCT in hematological malignancies with moderate to severe myelofibrosis.",[27,29,30,55],"Myelofibrosis (MF)","2026-04-13",{"date":58,"type":35},"2026-04-20",{"date":60,"type":20},"2026-05-01",{"date":39,"type":20},{"name":41,"class":42},""]